Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced presentation of preclinical ...

A study in Cancer Pathogenesis and Therapy finds ITGA3 expression in 85.2% of breast cancer specimens and links high levels ...

VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...

In BV2 microglial cells, esketamine suppressed lipopolysaccharide-induced M1 polarization by selectively acting on the NMDAR2A receptor subtype and activating mTOR and BDNF-TrkB signaling.

Fintel reports that on October 16, 2026, William Blair initiated coverage of Revolution Medicines (BMV:RVMD) with an Outperform recommendation. Revolution Medicines, Inc., based in the United States, ...

Faeth Therapeutics announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled ?Characterising the efficacy of ...

Kazia Therapeutics (KZIA) stock gains new Buy from Gueggenheim, based on company's lead asset paxalisib, following a similar view from Leerink this week. Read more here.

Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary closing conditions ...

Poster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancer; Poster ...

Researchers follow the children of centenarians to see what longevity and disease-resistance traits they may inherit. The ...

Culinary medicine integrates nutrition science with cooking education to help patients make healthier food choices and manage ...

MONARCH shows median OS of 32.1 vs 24.6 months with abemaciclib after prior CDK4/6 therapy, but the survival difference was ...